| Name | Fluticasone (propionate) |
| Description | Fluticasone propionate (CCI-187881), derived from fluticasone used to remedy asthma and allergic rhinitis, is a high affinity, selective GR (glucocorticoid receptor) agonist. |
| In vitro | Fluticasone propionate (1 pM) inhibits the constitutive and TGF-beta-induced expression of alpha-SMA in human lung myofibroblasts. Fluticasone propionate blocks the TNF-alpha-induced nuclear translocation of the pro-inflammatory transcription factor NF-kappaB in human lung myofibroblasts. [1] Fluticasone propionate inhibits in lung myofibroblasts, at a very early stage of differentiation, the activation of Janus kinase/STAT pathways induced by IL-13 (tyrosine kinase 2, STAT1, STAT3, STAT6, mitogen-activated protein kinase). Fluticasone propionate still displays a potential anti-inflammatory activity even if it only inhibits tyrosine kinase 2 phosphorylation in mildly or fully differentiated myofibroblastic cultures. Fluticasone propionate inhibits constitutive and TGF-beta-induced expression of alpha-smooth muscle actin, the main marker of myofibroblastic differentiation, both in very early and in mild differentiated myofibroblasts. Fluticasone propionate displays an additional powerful anti-inflammatory effect, decreasing nuclear translocation of NF-kappaB independent of the degree of myofibroblastic differentiation. [2] Fluticasone propionate inhibits allergen-induced T-cell proliferation, expression of IL-3, IL-5 and GM-CSF mRNA, and secretion of the corresponding proteins in a concentration-dependent fashion. Fluticasone propionate has the potential markedly to inhibit allergen-induced T-cell production of asthma-relevant cytokines. [3] |
| In vivo | Fluticasone propionate administrated after induction of a severe heaves exacerbation results in complete resolution of clinical signs, normalization of pulmonary function tests, and significant decrease in bronchoalveolar lavage (BAL) neutrophilia in horse. [4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/mL (119.86 mM), Sonication is recommended.
|
| Keywords | VirusProtease | Virus Protease | seasonal | Rhinovirus | rhinitis | progestogenReceptor | progestogen Receptor | perennial | Mineralocorticoid Receptor | Inhibitor | inhibit | HRVs | HRV | HEVs | HEV | GlucocorticoidReceptor | Glucocorticoid Receptor | Fluticasone Propionate | Fluticasone (propionate) | Fluticasone | EstrogenReceptor | Estrogen Receptor | ER | Enterovirus | EndogenousMetabolite | Endogenous Metabolite | Cytosolic PLA2 | corticosteroid | CCI187881 | CCI 187881 | bronchial | asthma | anti-inflammatory | allergic | ADCCytotoxin | ADC Cytotoxin |
| Inhibitors Related | Sucrose | Neomycin sulfate | Acetaminophen | Daidzein | Guanidine hydrochloride | Fumaric acid | Ferulic Acid | Formamide | Glycerol | Thymidine | Naringin | 3-Indoleacetic acid |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
